Reblozyl 75 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26F9X84
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,994
Award facts
- Contract value 100% obligated
- $25,993.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., received a delivery order award from the Defense Logistics Agency (DLA) on January 15, 2026, for the supply of Reblozyl 75 mg vials with a ceiling value of $25,993.83. This firm fixed-price delivery order is not set-aside and is scheduled for completion by February 6, 2026. Performance will be conducted at the vendor's corporate office in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
Reblozyl (luspatercept) is a specialty pharmaceutical product used in the treatment of certain blood disorders. This delivery order represents routine fulfillment of the company's broader pharmaceutical supply agreement with the Defense Logistics Agency, which enables AmerisourceBergen to deliver a vast range of medications, vaccines, medical devices, and specialized healthcare commodities to support military treatment facilities and veteran healthcare systems. AmerisourceBergen's competitive positioning in federal pharmaceutical procurement is demonstrated through its consistent receipt of non-set-aside awards and its status as a critical vendor in the defense medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F9X84?
SPE2DR26F9X84 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26F9X84 worth?
The government has obligated $25,994 on SPE2DR26F9X84.
Is contract SPE2DR26F9X84 an order under another contract?
Yes. SPE2DR26F9X84 is a delivery order under SPE2DR25D3103, an indefinite delivery contract.
Was contract SPE2DR26F9X84 competed?
The extent of competition for SPE2DR26F9X84 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award